NBTX · Nanobiotix S.A.
$29.36
+0.58% last session
End-of-day data · close of 2026-10-23
Market cap
$1B
Enterprise value
$1B
Trailing P/E
—
Forward P/E
-196.7
Dividend yield
0.0%
Beta
0.59
Avg volume
0M
Employees
0K
Daily Change %
0.58%
5 Days Change
39.28%
10 Days Change
37.97%
30 Days Change
-12.25%
60 Days Change
-29.27%
Month to Day Change
5.23%
Year to Day Change
26.99%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — NBTX
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-06-04
Latest call per bank · past 12 months
UBS
Neutral$30.00
+2.2% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-06-04 | Leerink Partners | Maintains | Outperform | $37.00 → $46.00 |
| 2026-05-01 | UBS | Maintains | Neutral | $3.50 → $30.00 |
| 2026-04-02 | Guggenheim | Maintains | Buy | $26.00 → $36.00 |
| 2026-02-06 | Guggenheim | Maintains | Buy | $8.00 → $26.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 55 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 12.2% below the 50-day MA ($33.43).
- bearish: Price vs 200-day MA: Trading 12.5% below the 200-day MA ($33.54).
- bearish: MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- bullish: MACD (12,26,9): MACD histogram is positive (+1.10) — short-term momentum is improving.
- neutral: 52-week range: Price sits between the 52-week low ($15.08) and high ($55.07).
NBTX Price Chart
Loading chart for NBTX…
Fundamentals
About Nanobiotix S.A.
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.